Additionally, inhibiting the binding of ALCAM to CD6 modulates lymphocyte trafficking and results in reduced T effector cell infiltration into inflamed tissues. Equillium is a clinical-stage ...
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
New Scientist on MSN1d
CAR T-cells enable record-breaking 18-year nerve cancer remissionA person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback